Search

Your search keyword '"Nanda, Kavinderjit"' showing total 31 results
Start Over Author "Nanda, Kavinderjit"
31 results on '"Nanda, Kavinderjit"'

4. Clinical and endoscopic predictors of cytological dysplasia or cancer in a prospective multicentre study of large sessile serrated adenomas/polyps

Author

Burgess, Nicholas G, Pellise, Maria, Nanda, Kavinderjit S, Hourigan, Luke F, Zanati, Simon A, Brown, Gregor J, Singh, Rajvinder, Williams, Stephen J, Raftopoulos, Spiro C, Ormonde, Donald, Moss, Alan, Byth, Karen, PʼNg, Heok, McLeod, Duncan, Bourke, Michael J, Mahajan, Hema, Bettington, Mark, Clouston, Andrew, Dow, Chris, Bhathal, Prithi, Pham, Alan, Ruszkiewicz, Andrew, McGivern, Andrina, and Kumarasinghe, Priyanthi

Published
2016
Full Text
View/download PDF

11. Clinical and endoscopic predictors of cytological dysplasia or cancer in a prospective multicentre study of large sessile serrated adenomas/polyps

Author

Burgess, Nicholas G, primary, Pellise, Maria, additional, Nanda, Kavinderjit S, additional, Hourigan, Luke F, additional, Zanati, Simon A, additional, Brown, Gregor J, additional, Singh, Rajvinder, additional, Williams, Stephen J, additional, Raftopoulos, Spiro C, additional, Ormonde, Donald, additional, Moss, Alan, additional, Byth, Karen, additional, P'Ng, Heok, additional, McLeod, Duncan, additional, and Bourke, Michael J, additional

Published
2015
Full Text
View/download PDF

22. Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine

Author

Nanda,Kavinderjit, Moss,Alan C, Nanda,Kavinderjit, and Moss,Alan C

Abstract

Kavinderjit Nanda, Alan C MossCenter for Inflammatory Bowel Disease, BIDMC/Harvard Medical School, Boston, MA, USAAbstract: Ulcerative colitis (UC) is a chronic inflammatory disease of the colon that typically manifests as diarrhea, abdominal pain, and bloody stool. Complications, such as colorectal cancer and extraintestinal manifestations, may also develop. The goals of management are to induce and maintain clinical remission and to screen for complications of this disease. Mesalamine is a 5-aminosalicylic acid compound that is the first-line therapy to induce and maintain clinical remission in patients with mild-to-moderate UC. For patients who are refractory to mesalamine or have more severe disease, steroids, azathioprine/mercaptopurine, cyclosporine, or infliximab may be used, induce and/or maintain remission. The various formulations of mesalamine available are primarily differentiated by the methods of delivery of the active compound of the drug to the colon. Mesalamine with Multi-Matrix System® (MMX) technology (Cosmo SpA, Milan, Italy) is an oral (1.2 g), once-daily tablet formulation of mesalamine used for the treatment of UC (Lialda® or Mezavant®, Shire Pharmaceuticals Inc, Wayne, PA). In clinical studies, MMX mesalamine (taken as a once-daily dose of 2.4 or 4.8 g) effectively induced and maintained clinical remission in patients with active mild-to-moderate UC. The overall safety profile of MMX mesalamine is similar to other oral mesalamine formulations. The use of such once-daily formulations has led to intense interest in whether simplified pill regimens can improve patient adherence to mesalamine therapy.Keywords: mesalamine, 5-ASA, ulcerative colitis, inflammatory bowel diseaseCorrigendum for this paper has been published

Published
2012

23. 505 Comparison of Large Sessile Serrated Adenoma Characteristics With Conventional Advanced Mucosal Neoplasia Resected by Wide Field Endoscopic Mucosal Resection in a Multicenter Prospective Cohort

Author

Burgess, Nicholas G., primary, Nanda, Kavinderjit S., additional, Williams, Stephen J., additional, Singh, Rajvinder, additional, Hourigan, Luke F., additional, Zanati, Simon a., additional, Brown, Gregor J., additional, Mcleod, Duncan J., additional, and Bourke, Michael J., additional

Published
2013
Full Text
View/download PDF

24. Su1036 Phenotypic Expression of Large (≥ 20mm) Sessile Serrated Adenomas of the Colon As a Predictor of High Grade Dysplasia or Colorectal Cancer in a Multicenter Prospective Cohort

Author

Nanda, Kavinderjit S., primary, Burgess, Nicholas G., additional, Williams, Stephen J., additional, Singh, Rajvinder, additional, Hourigan, Luke F., additional, Zanati, Simon A., additional, Brown, Gregor J., additional, Ward, Robyn L., additional, Sonson, Rebecca, additional, Acharya, Priya, additional, Byth, Karen, additional, and Bourke, Michael J., additional

Published
2013
Full Text
View/download PDF

30. Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine.

Author

Nanda, Kavinderjit and Moss, Alan C.

Subjects
ULCERATIVE colitis, INFLAMMATORY bowel diseases, ABDOMINAL pain, DISEASE management, DIARRHEA
Abstract

Ulcerative colitis (UC) is a chronic inflammatory disease of the colon that typically manifests as diarrhea, abdominal pain, and bloody stool. Complications, such as colorectal cancer and extraintestinal manifestations, may also develop. The goals of management are to induce and maintain clinical remission and to screen for complications of this disease. Mesalamine is a 5-aminosalicylic acid compound that is the first-line therapy to induce and maintain clinical remission in patients with mild-to-moderate UC. For patients who are refractory to mesalamine or have more severe disease, steroids, azathioprine/mercaptopurine, cyclosporine, or infliximab may be used, induce and/or maintain remission. The various formulations of mesalamine available are primarily differentiated by the methods of delivery of the active compound of the drug to the colon. Mesalamine with Multi-Matrix System® (MMX) technology (Cosmo SpA, Milan, Italy) is an oral (1.2 g), once-daily tablet formulation of mesalamine used for the treatment of UC (Lialda® or Mezavant®, Shire Pharmaceuticals Inc, Wayne, PA). In clinical studies, MMX mesalamine (taken as a once-daily dose of 2.4 or 4.8 g) effectively induced and maintained clinical remission in patients with active mild-to-moderate UC. The overall safety profile of MMX mesalamine is similar to other oral mesalamine formulations. The use of such once-daily formulations has led to intense interest in whether simplified pill regimens can improve patient adherence to mesalamine therapy. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

31. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis.

Author

O'Meara S, Nanda KS, and Moss AC

Subjects
Clinical Trials as Topic, Humans, Inflammatory Bowel Diseases blood, Infliximab, Infusions, Intravenous, Meta-Analysis as Topic, Prognosis, Risk Factors, Anti-Inflammatory Agents, Non-Steroidal adverse effects, Antibodies, Anti-Idiotypic blood, Antibodies, Monoclonal adverse effects, Drug Hypersensitivity immunology, Inflammatory Bowel Diseases drug therapy
Abstract

Objectives: Antibodies to infliximab (ATIs) have been associated with a risk of infusion reactions in some studies of patients with inflammatory bowel disease. However, many factors, such as immunomodulators and dosing schedule, may influence this association. The aim of this article was to provide a pooled estimate of the risk of infusion reactions according to patients' ATI status and analyze the relationship of immunomodulators to this risk., Design: Public databases were searched for eligible studies. Quality assessment was undertaken for all studies using Grading of Recommendations Assessment, Development and Evaluation criteria. Raw data from studies meeting inclusion criteria were pooled for meta-analysis of effect estimates. Sensitivity analysis was performed for all outcomes. Funnel plot was performed to assess for publication bias., Results: Eight studies met the inclusion criteria, with a pooled total of 1351 subjects. Seven of the 8 studies had a high risk of bias in at least 1 quality domain. The cumulative data indicated that there was a higher risk ratio (RR) of any acute infusion reaction (RR 2.4; 95% confidence interval [CI] 1.5-3.8, P < 0.001) and severe infusion reactions (RR 5.8, 95% CI 1.7-19, P = 0.004) in patients with ATIs when compared with patients without ATIs. The RR of delayed hypersensitivity reactions was not significantly different between ATI+ and ATI- patients (RR 2.8, 95% CI 0.2-33, P = 0.4). Patients prescribed immunomodulators during maintenance infliximab therapy had a reduction in their risk for ATI development (RR 0.6, 95% CI 0.4-0.9, P = 0.02) and infusion reactions (RR 0.6, 95% CI 0.4-0.8, P < 0.001)., Conclusions: The presence of ATIs is associated with a significantly higher risk of acute infusion reactions, but not delayed hypersensitivity reactions, in patients with inflammatory bowel disease. Concomitant immunomodulators reduce this risk.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results